Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Routine Clinical Care in Patients With Epilepsy

Next Previous
Trial Profile

A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Routine Clinical Care in Patients With Epilepsy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Absence epilepsy; Complex partial epilepsy; Epilepsy; Generalised epilepsy; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Sponsors Eisai Inc

    • Most Recent Events

    • 01 Sep 2021 Results assessing efficacy/safety of perampanel monotherapy in patients with epilepsy using data from clinical trial (study 342; n=89) and real-world use (studies 504; n=60 and 506; n=47), presented at the 34th International Epilepsy Congress.
    • 22 Apr 2021 Results assessing efficacy/safety of perampanel monotherapy in patients with epilepsy using data from study 504, 506 and 342 presented at the 73rd Annual Meeting of the American Academy of Neurology
    • 08 Dec 2020 Results assessing clinical evidence for perampanel monotherapy from following clinical studies: two retrospective non-interventional phase IV studies: NCT02736162 and NCT03208660; one open-label phase III study NCT03201900 presented at the 74th Annual Meeting of the American Epilepsy Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top